Baxter reports 5% sales growth and raises 2026 outlook

Baxter reported third-quarter 2026 sales of $2.98 billion, up 5% on both a reported and organic basis, with GAAP diluted EPS of $0.57 and adjusted diluted EPS of $0.58. The company raised its full-year 2026 guidance to 4%-5% reported sales growth, 3%-4% organic sales growth and adjusted diluted EPS of $2.05-$2.15, while completing a $600 million cash tender offer that retired $864 million of debt. Baxter’s board also declared a quarterly dividend of $0.01 per share, payable January 4, 2027, to shareholders of record November 27, 2026.